MXD3 and nonpapillary renal cell carcinoma: Previous studies have shown the association of MXD3 expression levels and genetic or epigenetic alterations with tumour stage, metastasis, TME, immune escape and drug sensitivity in 39 TCGA cancer types and subtypes, including ccRCC [45].